Journal of Urban Health

, Volume 82, Supplement 1, pp i120–i126

Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use

  • Thomas L. Patterson
  • Shirley J. Semple
  • James K. Zians
  • Steffanie A. Strathdee


Methamphetamine use has become a major problem among communities of men having sex with men (MSM), where it has been associated with high-risk behaviors. Methamphetamine is often combined with other drugs that may increase its risks and adverse health consequences. To examine differences in background characteristics, HIV-risk behaviors, and psychosocial variables among polydrug-using HIV-positive MSM, the researchers classified a sample of 261 HIV-positive, methamphetamine-using MSM into three user groups: (1) methamphetamine only; (2) methamphetamine, marijuana, and poppers (light polydrug users); and (3) methamphetamine and other drugs (e.g., cocaine, heroin, hallucinogens, and ketamine; heavy polydrug users). Only 5% reported using only methamphetamine during the past 2 months; 31% were classified as light polydrug users, and 64% were classified as heavy polydrug users. Heavy polydrug users were significantly younger than light polydrug users (35.6 vs. 38.4, P<.01) and reported using methamphetamine for significantly fewer years (10.3 vs. 14.2 years, P<.001), but did not differ in the amount and frequency of methamphetamine or alcohol consumed. Heavy polydrug users reported significantly more sex partners of HIV-negative and unknown serostatus and had more unprotected sex with these partners. Heavy polydrug users had significantly higher scores on impulsivity and negative self-perceptions, as compared with those of light polydrug users. In this sample of HIV-positive MSM, most of those who used methamphetamine had a pattern of polydrug use. Heavy polydrug users reported significantly more high-risk sexual behaviors and tended toward higher levels of impulsivity than light polydrug users. The implications of these findings are two-fold: (1) Longitudinal research is needed to establish causal relationships among methamphetamine use, impulsivity, negative self-perceptions, and sexual risk behavior in this target population; (2) behavioral interventions should evaluate whether methamphetamine use and sexual risk behavior can be reduced by modifying impulsivity and negative self-perceptions.


HIV Methamphetamine MSM Polydrug abuse Sexual risk 


  1. 1.
    Reback CJ. The Social Construction of a Gay Drug. Methamphetamine Use Among Gay and Bisexual Males in Los Angeles. Executive Summary. Los Angeles, CA: AIDS Coordinator; 1997.Google Scholar
  2. 2.
    National Institute of Justice. Meth Matters: Report on Methamphetamine Users in Five Western Cities. Washington, DC: US Department of Justice; 1999.Google Scholar
  3. 3.
    Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. U.S. HIV and AIDS cases reported through December 2001. Available at: stats/hasr1302.htm. Accessed October 23, 2004.Google Scholar
  4. 4.
    Greenwood GL, White EW, Page-Shafer K, et al. Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men’s Health Study. Drug Alcohol Depend. 2001;61:105–112.CrossRefPubMedGoogle Scholar
  5. 5.
    Stall R, Paul JP, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2001;96:1589–1601.CrossRefPubMedGoogle Scholar
  6. 6.
    Leri F, Bruneau J, Stewart U. Understanding polydrug use: review of heroin and cocaine use. Addiction. 2003;98:7–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee SJ, Galanter M, Dermatis H, McDowell D. Circuit parties and patterns of drug use in a subset of gay men. J Addict Dis. 2003;22:47–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Romanelli F, Smith KM, Pomeroy C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top HIV Med. 2003;11:25–32.PubMedGoogle Scholar
  9. 9.
    Craib KJ, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003;168:19–24.PubMedGoogle Scholar
  10. 10.
    Ochoa KC, Hahn JA, Seal KH, Moss AR. Overdosing among young injection drug users in San Francisco. Addict Behav. 2001;26:453–460.CrossRefPubMedGoogle Scholar
  11. 11.
    Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIV+men who have sex with men. J Subst Abuse Treat. 2002;22:149–156.CrossRefPubMedGoogle Scholar
  12. 12.
    Centers for Disease Control, Division of HIV/AIDS Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1–17.Google Scholar
  13. 13.
    Beck AT. Depression: Clinical, Experimental and Theoretical Aspects. New York, NY: Harper & Row; 1967.Google Scholar
  14. 14.
    Beck AT. Cognitive Therapy and Emotional Disorder. New York, NY: Hoeber; 1976.Google Scholar
  15. 15.
    Bucholz KK, Cadoret R, Cloninger RD et al. A new semi-structured psychiatric interview for use in genetic linkage studies. A report on the reliability of the SSAGA. J Stud Alcohol. 1994;55:149–158.PubMedGoogle Scholar
  16. 16.
    Bucholz KK, Hesselbrock VM, Shayka JJ, et al. Reliability of individual diagnostic criterion items for psychoactive substance dependence and the impact on diagnosis. J Stud Alcohol. 1995;56:500–505.PubMedGoogle Scholar
  17. 17.
    Saunders B, Houghton M. Relapse revisited: a critique of current concepts and clinical practice in the management of alcohol problems. Addict Behav. 1996;21:843–855.CrossRefPubMedGoogle Scholar
  18. 18.
    San Diego Association of Governments. Methamphetamine. Unpublished manuscript. Available at Accessed April 15, 2004.Google Scholar
  19. 19.
    Dickman SJ. Functional and dysfunctional impulsivity: personality and cognitive correlates. J Pers Soc Psychol. 1990;58:95–102.CrossRefPubMedGoogle Scholar
  20. 20.
    Moeller FG, Dougherty DM, Barratt ES, Schmitz JM, Swann AC, Grabowski J. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat. 2001;21:193–198.CrossRefPubMedGoogle Scholar
  21. 21.
    Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997;38:177–190.CrossRefPubMedGoogle Scholar
  22. 22.
    Schaefer C, Coyne JC, Lazarus R. The health-related functions of social support. J Behav Med. 1981;4:381–406.CrossRefPubMedGoogle Scholar
  23. 23.
    Nugent WR, Thomas JW. Validation of a clinical measure of self-esteem. Res Soc Work Pract. 1993;3:191–207.Google Scholar
  24. 24.
    Carneiro M, Fuller C, Doherty MC, Vlahov D. HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old. Drug Alcohol Depend. 1999;54:83–86.CrossRefPubMedGoogle Scholar
  25. 25.
    Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Nelson K. Sex differences in risk factors for HIV seroconversion among injection drug users. Arch Intern Med. 2001;161:1281–1288.CrossRefPubMedGoogle Scholar
  26. 26.
    Reback CJ, Larkins S, Shoptaw S. Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav. 2004;8:87–98.CrossRefPubMedGoogle Scholar
  27. 27.
    Semple SJ, Patterson TL, Grant I. Negative Self-Perceptions and Sexual Risk Behavior Among Heterosexual Methamphetamine Users. Unpublished manuscript.Google Scholar
  28. 28.
    Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. Unpublished manuscript.Google Scholar

Copyright information

© Oxford University Press on behalf of the New York Academy of Medicine 2005

Authors and Affiliations

  • Thomas L. Patterson
    • 3
    • 1
  • Shirley J. Semple
    • 3
  • James K. Zians
    • 3
  • Steffanie A. Strathdee
    • 2
  1. 1.Department of Veterans Affairs Medical CenterSan DiegoCalifornia
  2. 2.Department of Family and Preventive MedicineUniversity of CaliforniaSan Diego, La JollaCalifornia
  3. 3.Department of Psychiatry (0680)University of CaliforniaSan Diego

Personalised recommendations